Last updated
Legend Biotech Corporation: Capital Raising
Legend Biotech announced a $225 million underwritten public offering of American Depositary Shares with a 30-day greenshoe option for up to 15% additional shares.
Source: GNW — Contract Announcements
The leadership read
Legend Biotech Corporation's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.
Market context: Against a Talent Market Index of 100.2 (Neutral) (down 1.1 month-on-month), Americas is at easing (-1.8pts) on signal share.
Legend Biotech Corporation: 1 signal in the last 90 days — below the Biotech & Pharma median of 1.5 across 24 tracked companies.
MitchelLake in this thematic
More signals across Biotech & Pharma
Capital Raising · Americas
Twist Bioscience →Twist Bioscience completed a US$300 million follow-on equity offering at US$96/share, upsized from an initially filed US$250 million raise. Concurrent with Q3 2026 results showing US$118.38M revenue and US$35.05M loss, company raised FY2026 guidance to US$456-457M.
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Capital Raising · Americas
Sana Biotechnology, Inc. →Schedule 13G filing indicates potential significant ownership change or investment activity
Ma Activity · Americas
Amgen →Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
Ma Activity · Americas
BioMarin Pharmaceutical Inc. →BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.
Where this lands in our work
- Executive Search →
Capital raised becomes leadership hired — the executive build follows the announcement.
- Executive Search — Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗